Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentric Phase II Trial of Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation

NCT03955198 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.

NCT NCT03955198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03955198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentric Phase II Trial of Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation
Lead sponsor
Institut Claudius Regaud
Phase
Phase 2
Overall status
Completed
Start date
May 27, 2021
Completion date
August 26, 2024
Enrollment
4 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc